Aurora-A kinase inhibition enhances the cytosine arabinoside-induced cell death in leukemia cells through apoptosis and mitotic catastrophe

Cancer Letters

Volumn 297, Issue 2, 2010, Pages 171-181

  Cheong, June Won ^a   Jung, Haeng Im ^a   Eom, Ju In ^a   Kim, Soo Jung ^a   Jeung, Hoi Kyung ^a   Min, Yoo Hong ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Acute leukemia; Apoptosis; Ara C; Aurora kinase; Mitotic catastrophe

Indexed keywords

AURORA A KINASE; CYTARABINE; MITOGEN ACTIVATED PROTEIN KINASE P38; AURORA KINASE; CASPASE; PROTEIN SERINE THREONINE KINASE; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; ENZYME INHIBITION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LEUKEMIA CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOSIS; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DRUG EFFECTS; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; HL 60 CELL LINE; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MITOCHONDRION; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CASPASES; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; CYTARABINE; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; MITOSIS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; RNA, SMALL INTERFERING; TRANSFECTION; AURORA KINASES;

ARA;

EID: 77956407435     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.05.009     Document Type: Article

References (67)

1. Byrd J.C., Mrozek K., Dodge R.K., Carroll A.J., Edwards C.G., Arthur D.C., Pettenati M.J., Patil S.R., Rao K.W., Watson M.S., Koduru P.R., Moore J.O., Stone R.M., Mayer R.J., Feldman E.J., Davey F.R., Schiffer C.A., Larson R.A., Bloomfield C.D. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100:4325-4336.
2. Tallman M.S. New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents. Hematology Am. Soc. Hematol. Educ. Program 2005, 143-150.
3. Marcucci G., Mrozek K., Ruppert A.S., Archer K.J., Pettenati M.J., Heerema N.A., Carroll A.J., Koduru P.R., Kolitz J.E., Sterling L.J., Edwards C.G., Anastasi J., Larson R.A., Bloomfield C.D. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. J. Clin. Oncol. 2004, 22:2410-2418.
4. Estey E., Dohner H. Acute myeloid leukaemia. Lancet 2006, 368:1894-1907.
5. Cros E., Jordheim L., Dumontet C., Galmarini C.M. Problems related to resistance to cytarabine in acute myeloid leukemia. Leuk. Lymphoma 2004, 45:1123-1132.
6. Nigg E.A. Mitotic kinases as regulators of cell division and its checkpoints. Nat. Rev. Mol. Cell Biol. 2001, 2:21-32.
7. Marumoto T., Honda S., Hara T., Nitta M., Hirota T., Kohmura E., Saya H. Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J. Biol. Chem. 2003, 278:51786-51795.
8. Marumoto T., Zhang D., Saya H. Aurora-A - a guardian of poles. Nat. Rev. Cancer 2005, 5:42-50.
9. Carmena M., Earnshaw W.C. The cellular geography of aurora kinases. Nat. Rev. Mol. Cell Biol. 2003, 4:842-854.
10. Katayama H., Brinkley W.R., Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev. 2003, 22:451-464.
11. Keen N., Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat. Rev. Cancer 2004, 4:927-936.
12. Fu J., Bian M., Jiang Q., Zhang C. Roles of Aurora kinases in mitosis and tumorigenesis. Mol. Cancer Res. 2007, 5:1-10.
13. Kufer T.A., Sillje H.H., Korner R., Gruss O.J., Meraldi P., Nigg E.A. Human TPX2 is required for targeting Aurora-A kinase to the spindle. J. Cell Biol. 2002, 158:617-623.
14. Katayama H., Sasai K., Kawai H., Yuan Z.M., Bondaruk J., Suzuki F., Fujii S., Arlinghaus R.B., Czerniak B.A., Sen S. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat. Genet. 2004, 36:55-62.
15. Zhou H., Kuang J., Zhong L., Kuo W.L., Gray J.W., Sahin A., Brinkley B.R., Sen S. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat. Genet. 1998, 20:189-193.
16. Bischoff J.R., Anderson L., Zhu Y., Mossie K., Ng L., Souza B., Schryver B., Flanagan P., Clairvoyant F., Ginther C., Chan C.S., Novotny M., Slamon D.J., Plowman G.D. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 1998, 17:3052-3065.
17. Carvajal R.D., Tse A., Schwartz G.K. Aurora kinases: new targets for cancer therapy. Clin. Cancer Res. 2006, 12:6869-6875.
18. Sen S., Zhou H., Zhang R.D., Yoon D.S., Vakar-Lopez F., Ito S., Jiang F., Johnston D., Grossman H.B., Ruifrok A.C., Katz R.L., Brinkley W., Czerniak B. Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J. Natl. Cancer Inst. 2002, 94:1320-1329.
19. Yamamoto Y., Matsuyama H., Kawauchi S., Furuya T., Liu X.P., Ikemoto K., Oga A., Naito K., Sasaki K. Biological characteristics in bladder cancer depend on the type of genetic instability. Clin. Cancer Res. 2006, 12:2752-2758.
20. Li D., Zhu J., Firozi P.F., Abbruzzese J.L., Evans D.B., Cleary K., Friess H., Sen S. Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin. Cancer Res. 2003, 9:991-997.
21. Lee E.C., Frolov A., Li R., Ayala G., Greenberg N.M. Targeting Aurora kinases for the treatment of prostate cancer. Cancer Res. 2006, 66:4996-5002.
22. Miyoshi Y., Iwao K., Egawa C., Noguchi S. Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int. J. Cancer 2001, 92:370-373.
23. Crosio C., Fimia G.M., Loury R., Kimura M., Okano Y., Zhou H., Sen S., Allis C.D., Sassone-Corsi P. Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol. Cell Biol. 2002, 22:874-885.
24. Tanaka E., Hashimoto Y., Ito T., Kondo K., Higashiyama M., Tsunoda S., Ortiz C., Sakai Y., Inazawa J., Shimada Y. The suppression of aurora-A/STK15/BTAK expression enhances chemosensitivity to docetaxel in human esophageal squamous cell carcinoma. Clin. Cancer Res. 2007, 13:1331-1340.
25. Ikezoe T., Yang J., Nishioka C., Tasaka T., Taniguchi A., Kuwayama Y., Komatsu N., Bandobashi K., Togitani K., Koeffler H.P., Taguchi H. A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia. Mol. Cancer Ther. 2007, 6:1851-1857.
26. Huang X.F., Luo S.K., Xu J., Li J., Xu D.R., Wang L.H., Yan M., Wang X.R., Wan X.B., Zheng F.M., Zeng Y.X., Liu Q. Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia. Blood 2008, 111:2854-2865.
27. Walsby E., Walsh V., Pepper C., Burnett A., Mills K. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. Haematologica 2008, 93:662-669.
28. Harrington E.A., Bebbington D., Moore J., Rasmussen R.K., Ajose-Adeogun A.O., Nakayama T., Graham J.A., Demur C., Hercend T., Diu-Hercend A., Su M., Golec J.M., Miller K.M. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat. Med. 2004, 10:262-267.
29. Shi Y., Reiman T., Li W., Maxwell C.A., Sen S., Pilarski L., Daniels T.R., Penichet M.L., Feldman R., Lichtenstein A. Targeting aurora kinases as therapy in multiple myeloma. Blood 2007, 109:3915-3921.
30. Giles F.J., Cortes J., Jones D., Bergstrom D., Kantarjian H., Freedman S.J. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007, 109:500-502.
31. Shah N.P., Skaggs B.J., Branford S., Hughes T.P., Nicoll J.M., Paquette R.L., Sawyers C.L. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J. Clin. Invest. 2007, 117:2562-2569.
32. Yang J., Ikezoe T., Nishioka C., Tasaka T., Taniguchi A., Kuwayama Y., Komatsu N., Bandobashi K., Togitani K., Koeffler H.P., Taguchi H., Yokoyama A. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood 2007, 110:2034-2040.
33. Sun C., Chan F., Briassouli P., Linardopoulos S. Aurora kinase inhibition downregulates NF-kappaB and sensitises tumour cells to chemotherapeutic agents. Biochem. Biophys. Res. Commun. 2007, 352:220-225.
34. Hata T., Furukawa T., Sunamura M., Egawa S., Motoi F., Ohmura N., Marumoto T., Saya H., Horii A. RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res. 2005, 65:2899-2905.
35. Li J., Anderson M.G., Tucker L.A., Shen Y., Glaser K.B., Shah O.J. Inhibition of Aurora B kinase sensitizes a subset of human glioma cells to TRAIL concomitant with induction of TRAIL-R2. Cell Death Differ. 2009, 16:498-511.
36. Tao Y., Zhang P., Frascogna V., Lecluse Y., Auperin A., Bourhis J., Deutsch E. Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells. Br. J. Cancer 2007, 97:1664-1672.
37. Tao Y., Zhang P., Girdler F., Frascogna V., Castedo M., Bourhis J., Kroemer G., Deutsch E. Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152. Oncogene 2008, 27:3244-3255.
38. Fiskus W., Wang Y., Joshi R., Rao R., Yang Y., Chen J., Kolhe R., Balusu R., Eaton K., Lee P., Ustun C., Jillella A., Buser C.A., Peiper S., Bhalla K. Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin. Cancer Res. 2008, 14:6106-6115.
39. Cheong J.W., Chong S.Y., Kim J.Y., Eom J.I., Jeung H.K., Maeng H.Y., Lee S.T., Min Y.H. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells. Clin. Cancer Res. 2003, 9:5018-5027.
40. Wilkinson R.W., Odedra R., Heaton S.P., Wedge S.R., Keen N.J., Crafter C., Foster J.R., Brady M.C., Bigley A., Brown E., Byth K.F., Barrass N.C., Mundt K.E., Foote K.M., Heron N.M., Jung F.H., Mortlock A.A., Boyle F.T., Green S. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin. Cancer Res. 2007, 13:3682-3688.
41. Gizatullin F., Yao Y., Kung V., Harding M.W., Loda M., Shapiro G.I. The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res. 2006, 66:7668-7677.
42. Dar A.A., Belkhiri A., Ecsedy J., Zaika A., El-Rifai W. Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells. Cancer Res. 2008, 68:8998-9004.
43. Ditchfield C., Johnson V.L., Tighe A., Ellston R., Haworth C., Johnson T., Mortlock A., Keen N., Taylor S.S. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J. Cell Biol. 2003, 161:267-280.
44. Chan F., Sun C., Perumal M., Nguyen Q.D., Bavetsias V., McDonald E., Martins V., Wilsher N.E., Raynaud F.I., Valenti M., Eccles S., Te Poele R., Workman P., Aboagye E.O., Linardopoulos S. Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. Mol. Cancer Ther. 2007, 6:3147-3157.
45. Dreier M.R., Grabovich A.Z., Katusin J.D., Taylor W.R. Short and long-term tumor cell responses to Aurora kinase inhibitors. Exp. Cell Res. 2009, 315:1085-1099.
46. Coltella N., Rasola A., Nano E., Bardella C., Fassetta M., Filigheddu N., Graziani A., Comoglio P.M., Di Renzo M.F. p38 MAPK turns hepatocyte growth factor to a death signal that commits ovarian cancer cells to chemotherapy-induced apoptosis. Int. J. Cancer 2006, 118:2981-2990.
47. Li W., Bertino J.R. Fas-mediated signaling enhances sensitivity of human soft tissue sarcoma cells to anticancer drugs by activation of p38 kinase. Mol. Cancer Ther. 2002, 1:1343-1348.
48. Baldwin R.M., Garratt-Lalonde M., Parolin D.A., Krzyzanowski P.M., Andrade M.A., Lorimer I.A. Protection of glioblastoma cells from cisplatin cytotoxicity via protein kinase Ciota-mediated attenuation of p38 MAP kinase signaling. Oncogene 2006, 25:2909-2919.
49. Xing H., Cao Y., Weng D., Tao W., Song X., Wang W., Meng L., Xu G., Zhou J., Wang S., Ma D. Fibronectin-mediated activation of Akt2 protects human ovarian and breast cancer cells from docetaxel-induced apoptosis via inhibition of the p38 pathway. Apoptosis 2008, 13:213-223.
50. Ngan C.Y., Yamamoto H., Takagi A., Fujie Y., Takemasa I., Ikeda M., Takahashi-Yanaga F., Sasaguri T., Sekimoto M., Matsuura N., Monden M. Oxaliplatin induces mitotic catastrophe and apoptosis in esophageal cancer cells. Cancer Sci. 2008, 99:129-139.
51. Park S.S., Kim M.A., Eom Y.W., Choi K.S. Bcl-xL blocks high dose doxorubicin-induced apoptosis but not low dose doxorubicin-induced cell death through mitotic catastrophe. Biochem. Biophys. Res. Commun. 2007, 363:1044-1049.
52. Strauss S.J., Higginbottom K., Juliger S., Maharaj L., Allen P., Schenkein D., Lister T.A., Joel S.P. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. Cancer Res. 2007, 67:2783-2790.
53. Vakifahmetoglu H., Olsson M., Zhivotovsky B. Death through a tragedy: mitotic catastrophe. Cell Death Differ. 2008, 15:1153-1162.
54. Roninson I.B., Broude E.V., Chang B.D. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug. Resist. Updat. 2001, 4:303-313.
55. Jackson J.R., Patrick D.R., Dar M.M., Huang P.S. Targeted anti-mitotic therapies: can we improve on tubulin agents?. Nat. Rev. Cancer 2007, 7:107-117.
56. Russell P., Nurse P. cdc25+ functions as an inducer in the mitotic control of fission yeast. Cell 1986, 45:145-153.
57. Okada H., Mak T.W. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat. Rev. Cancer 2004, 4:592-603.
58. Chan T.A., Hermeking H., Lengauer C., Kinzler K.W., Vogelstein B. 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 1999, 401:616-620.
59. Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., Altieri D.C. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396:580-584.
60. Mantel C., Braun S.E., Reid S., Henegariu O., Liu L., Hangoc G., Broxmeyer H.E. p21(cip-1/waf-1) deficiency causes deformed nuclear architecture, centriole overduplication, polyploidy, and relaxed microtubule damage checkpoints in human hematopoietic cells. Blood 1999, 93:1390-1398.
61. Scaife R.M. G2 cell cycle arrest, down-regulation of cyclin B, and induction of mitotic catastrophe by the flavoprotein inhibitor diphenyleneiodonium. Mol. Cancer Ther. 2004, 3:1229-1237.
62. Sahu R.P., Batra S., Srivastava S.K. Activation of ATM/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells. Br. J. Cancer 2009, 100:1425-1433.
63. Choi H.J., Yee S., Park S.E., Im E., Jung J.H., Chung H.Y., Choi Y.H., Kim N.D. Petrotetrayndiol A induces cell cycle arrest and apoptosis in SK-MEL-2 human melanoma cells through cytochrome c-mediated activation of caspases. Cancer Lett. 2006, 232:214-225.
64. Tarnawski A., Pai R., Chiou S.K., Chai J., Chu E.C. Rebamipide inhibits gastric cancer growth by targeting survivin and Aurora-B. Biochem. Biophys. Res. Commun. 2005, 334:207-212.
65. Choi J.A., Kim J.Y., Lee J.Y., Kang C.M., Kwon H.J., Yoo Y.D., Kim T.W., Lee Y.S., Lee S.J. Induction of cell cycle arrest and apoptosis in human breast cancer cells by quercetin. Int. J. Oncol. 2001, 19:837-844.
66. Shimomura T., Hasako S., Nakatsuru Y., Mita T., Ichikawa K., Kodera T., Sakai T., Nambu T., Miyamoto M., Takahashi I., Miki S., Kawanishi N., Ohkubo M., Kotani H., Iwasawa Y. MK-5108, a highly selective aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel. Mol. Cancer Ther. 2010, 9:157-166.
67. Wolanin K., Magalska A., Mosieniak G., Klinger R., McKenna S., Vejda S., Sikora E., Piwocka K. Curcumin affects components of the chromosomal passenger complex and induces mitotic catastrophe in apoptosis-resistant Bcr-Abl-expressing cells. Mol. Cancer Res. 2006, 4:457-469.